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Introduction {#sec1}
============

Chiral *syn*-1,3-diols are ubiquitous and privileged structural motifs in many biologically active polyketide natural products, most prominently represented by the macrolide antibiotics([@bib30], [@bib43], [@bib26]), and a range of small-molecule drugs, particularly in the statin families (HMG-CoA reductase inhibitors) ([Scheme 1](#sch1){ref-type="fig"}) ([@bib28], [@bib9], [@bib39]). In addition to direct incorporation into these molecules, chiral *syn*-1,3-diols are also fundamental building blocks that can easily be elaborated into complex natural products and bioactive molecules. The applications of chiral *syn*-1,3-diols are also a subject of increasing interest in the pharmaceutical industry ([@bib6], [@bib18], [@bib15], [@bib22], [@bib31], [@bib19], [@bib2]). For example, a statin analog, rosuvastatin, is used to treat hypercholesterolemia and prevent cardiovascular disease ([@bib35], [@bib23]), and achieved sales of \$4.2 billion in 2017. The unique *syn*-1,3-diols structure, together with their broad spectrum of physiological activities, fueled intense research activity into their synthesis. Benchmarked by the aldol-directed addition/reduction transformations ([@bib24], [@bib42]), a considerable number of ingenious methodologies with general utility have been developed. However, the relative and absolute stereocontrol in the construction of these structurally diverse chiral *syn*-1,3-diols still represents significant challenges. Only a few chiral *syn*-1,3-diol fragments with proper functional groups, such as aryl, acetate, nitrile and amine, are available. Those involving halogen-functionalized chiral *syn*-1,3-diols, which are versatile building blocks for the synthesis of *syn*-1,3-diol-containing natural products and drugs, are much less common. Therefore, there is still a great need for alternative, flexible, and highly stereoselective synthetic methodologies to construct chiral *syn*-1,3-diol scaffolds.Scheme 11,3-Diol Polyketide Natural Products and Drugs

Today, the stereocontrolled synthesis of chiral *syn*-1,3-diols can be achieved by the following two strategies: (1) catalyst-controlled asymmetric reactions ([Scheme 2](#sch2){ref-type="fig"}A) ([@bib18]) and (2) substrate-controlled asymmetric induction, both of which encompass a variety of possible bond disconnections around the hydroxy groups at the C1 and C3 positions. Although various transition metal catalysts and organocatalysts have been developed, no generally applicable approach exists for the flexible synthesis of chiral *syn*-1,3-diols, and the efficient construction of chiral *syn*-1,3-diol motifs was realized mainly by a classical Narasaka-Prasad reduction, that is, by securing the chirality of a *β*-hydroxyketone precursor and then ensuring a *syn*-diastereoselective reduction using excess Et~2~BOMe ([Scheme 2](#sch2){ref-type="fig"}B) ([@bib29], [@bib11]). Despite the considerable efficacy, cryogenic reaction conditions are required to achieve high diastereoselectivity. Notably, among several possible approaches to prepare functionalized chiral *syn*-1,3-diols, the direct diastereoselective electrophilic iodocarboxylation of homoallylic alcohols is clearly underexploited ([Scheme 2](#sch2){ref-type="fig"}C) ([@bib1], [@bib4], [@bib16], [@bib41]). Although this method requires additional transformation to extend the nucleophilic character of *β*-hydroxy group by forming esters such as cyclic phosphates and carbonates, the method allows the installation of the functionalized chiral *syn*-1,3-diol subunits in one step with high efficiency. However, this iodocarboxylation is limited by the inherent instability of the expensive iodo-1,3-dicarbonate products, and there are no reported diastereoselective bromocarboxylations using the chemical fixation of CO~2~ with chiral homoallylic alcohols to generate chiral *syn*-1,3-diols.Scheme 2Methods for the Synthesis of *syn*-1,3-Diols(A--D) (A) Hydrogenation of 1,3-hydroxyketones to chiral *syn*-1,3-diols. (B) Cryogenic Narasaka-Prasad reduction to chiral *syn*-1,3-diols (currently dominates in the industry). (C) ^n^BuLi-mediated iodocarboxylation to racemic *syn*-1,3-diols. (D) This work: substrate-induced diastereoselective bromocarboxylation to chiral *syn*-1,3-diols.

In our attempt to synthesize chiral *syn*-1,3-diol building blocks, we envisioned that CO~2~ could be an ideal oxygen source to introduce the second hydroxy group when using homoallylic alcohols. However, due to its thermodynamic stability, the chemical fixation of CO~2~ and its application in the production of valuable fine chemicals still represent major challenges ([@bib21], [@bib25], [@bib3], [@bib34]). In previous transformations involving CO~2~ fixation to unsaturated alcohols, strong bases (such as ^n^BuLi, [Scheme 2](#sch2){ref-type="fig"}C), or high CO~2~ pressures, were generally required ([@bib8], [@bib7], [@bib37], [@bib20], [@bib44]). In 2010, Minakata and coworkers described an innovative and extremely mild procedure for the synthesis of *trans*-1,2-diol ([@bib27]). Inspired by these fundamental results, we hypothesized that a transient alkylcarbonic acid, *in situ* prepared from CO~2~ and a homoallylic alcohol, could react with a cyclic bromonium intermediate in the presence of ^t^BuOCl and NaBr to give *syn*-1,3-diols ([Scheme 2](#sch2){ref-type="fig"}D). Moreover, the chirality of *syn*-1,3-diols could be obtained via chiral homoallylic alcohol transfer. Herein, we described the first stereocontrolled synthesis of chiral *syn-*1,3-diol motifs via a one-pot CO~2~ fixation/bromocyclization using various chiral homoallylic alcohols under extremely mild conditions in up to 91% yield, \>99% ee, and \>19:1 *dr*. This 1,3-asymmetric induction methodology was successfully applied in the asymmetric total synthesis of statins on the pilot plant scale.

Results and Discussion {#sec2}
======================

To validate the feasibility of our hypothesis, we first investigated the reaction using chiral homoallylic alcohol (**1a**) and ^t^BuOCl (2 equiv) with KBr (1.5 equiv) under a balloon of CO~2~ in acetonitrile at −20°C. As shown in [Table 1](#tbl1){ref-type="table"}, the desired chiral six-membered cyclic bromocarbonate **2a** was generated in 16% isolated yield with excellent diastereoselectivity (\>19:1, entry 1). To improve the efficiency of this bromocyclization, a variety of solvents were evaluated. Switching to a less polar solvent, THF, resulted in only 10% yield but good diastereoselectivity (entry 2). When using dichloromethane or ethyl acetate, the desired product was not formed even after a longer reaction time (entries 3 and 4). In comparison, the use of DMF (N,N-Dimethylformamide) as the solvent tremendously improved the yield of 2a to 65% (entry 5), which can be attributed to the good solubility of NaBr in DMF. However, kindred dimethylacetamide (DMA) led to an inferior yield (entry 6). When protic solvents, such as MeOH or HOAc, were employed, consumption of substrate **1** was detected, but no bromocarbonate product was detected (entries 7 and 8).Table 1Screening Conditions for the Bromocarboxylation of Chiral Homoallylic Alcohols![](fx2.gif)EntryMBr^t^BuOCl (eq)CO~2~ (atm)SolventTemp (°C)T (h)Yield (%)[a](#tblfn1){ref-type="table-fn"}, [b](#tblfn2){ref-type="table-fn"}dr[c](#tblfn3){ref-type="table-fn"}1KBr21MeCN−20316\>19:12KBr21THF−20310\>19:13KBr21DCM−205\<5--4KBr21EA−205\<5--5KBr21DMF−201.565\>19:16KBr21DMAc−20121\>19:17KBr21MeOH−205\<5--8KBr21HOAc−205\<5--9NH~4~Br21DMF−202\<5--10LiBr21DMF−201.5\<5--11NaBr21DMF−20173\>19:112NaBr21DMFr.t0.535\>19:113NaBr21DMF00.552\>19:114NaBr21DMF−10161\>19:115NaBr21DMF−30281\>19:116NaBr21DMF−40386\>19:117NaBr21DMF−50384\>19:118NaBr1.51DMF−40369\>19:119NaBr11DMF−40341\>19:120NaBr2.51DMF−40387\>19:121NaBr25DMF−40388\>19:122NaBr210DMF−40387\>19:1[^2][^3][^4][^5]

We next investigated other representative alkali metal bromides, including NaBr, NH~4~Br, and LiBr (entries 9--11). NaBr proved to be a superior bromination reagent with high reactivity and selectivity, giving the desired product in 73% yield in 1 hr (entry 11). In contrast, more soluble bromides, NH~4~Br and LiBr, failed to produce expected bromocarbonate **2a** (entries 9 and 10). The reaction temperatures were also examined, and the reaction yields were dependent on the temperatures. Increasing the temperature led to decreased reaction yields and diastereoselectivities (entries 12--15). In contrast, the formation of **2a** could be improved by conducting the reaction at lower temperatures. At −40°C, the reaction afforded the optimal results with 86% yield and \>19:1 diastereoselectivity within 3 hr (entry 16). When the temperature was decreased further, the yield of the reaction remained essentially the same (entry 17).

Changing the equivalence of ^t^BuOCl and CO~2~ was also discussed. Decreasing the amount of ^t^BuOCl significantly decreased the yield of this reaction (entries 18 and 19), whereas increasing the amount did not improve the yield (entry 20). Simultaneously, improving the pressure of CO~2~ slightly improved the yield but special equipment was needed, which made the procedure impractical (entries 21, 22). Thus, we selected ^t^BuOCl (2 equiv) with NaBr(1.5 equiv) under a balloon of CO~2~ in DMF and at −40°C as the reaction conditions. Notably, when using iodide as the nucleophile, no desired *syn*-1,3-diol was produced, suggesting that iodide was not suitable for this reaction.

With the optimized reaction conditions in hand, we investigated the substrate scope of this reaction with various chiral homoallylic alcohols. As illustrated in [Table 2](#tbl2){ref-type="table"}, this new system indicated excellent substrate compatibility, giving the desired carbonate products in good to excellent isolated yields and diastereoselectivities. First, the ester-containing substrates performed well and afforded the desired *syn*-isomer products in excellent yields (79%--86%) and high diastereoselectivities (\>19:1) (**2a-e**). Replacing the ester groups with various oxy groups, including electron-rich benzyloxy (**2f, 2g**), electron-deficient p-toluenesulfonic ester (OT)s (**2h**), or sterically bulky alkoxy (**2i, 2j**) or silyloxy groups (**2k, 2l**), all led to bromocarbonate products in identical performances. With general alkyl (**2m**), benzyl (**2n, 2o**), or aryl substituents (**2p, 2q**), this reaction also worked well and produced the desired products. In addition, heterocycles, such as thienyl (**2r**), reacted smoothly to give the desired product in good yield and diastereoselectivity. Moreover, some highly reactive functional groups, such as Cl (**2s**) and CN (**2t**), were also tolerated under these reaction conditions. Substrates bearing geminal substituents were also converted into the corresponding products (**2u**). Notably, when homoallylic alcohols with mono- (**2v, 2w**) or disubstituted (**2x, 2y**) double bonds were used, the carbonate products were generated in moderate yields (25%--45%), but the good diastereoselectivities remained. To further evaluate the synthetic utility of this method, we attempted to use the opposite configuration of the (*S*)-homoallylic alcohols. Fortunately, satisfactory yields and diastereoselectivities were obtained with all these substrates, which not only highlighted the excellent substrate compatibility but also implied the great potential of this new method for synthesizing chiral *syn*-1,3-diols (**3a**-**e**). More importantly, the enantiopurity of the starting material was retained, and 99% ee was detected in all cases after purification.Table 2Survey of the Substrate Scope in the Diastereoselective Bromocarboxylation of Chiral Homoallylicalcohols![](fx3.gif)

Industrial Application {#sec2.1}
----------------------

The aforementioned chiral *syn*-1,3-diol-bromocarbonates are valuable building blocks for the asymmetric synthesis of *syn*-1,3-diol-containing natural products and drugs, and the power of this methodology was demonstrated in the pilot-plant-scale synthesis of chiral *syn*-1,3-diol-derived statins, including rosuvastatin, pitavastatin, and atorvastatin. As depicted in [Scheme 3](#sch3){ref-type="fig"}, chiral homoallylic alcohol **1a** was subjected to ^t^BuOCl and NaBr in DMF at −40°C under a continuously bubbling CO~2~ system to give, after crystallization, pure bromocarbonate product **2a** in 76% yield, \>99% ee, and \>19:1 *dr* without column chromatography isolation. Compound **2a** was then converted to acetate **7** in two steps via acetonidation ([@bib14], [@bib33], [@bib5]) followed by an S~N~2 reaction with a total yield of 74%. Subsequent hydrolysis of the acetate proceeded smoothly to give Kaneka alcohol **8** in 93% yield ([@bib17], [@bib36]), which could be transformed to the final rosuvastatin **9** via known procedures ([@bib38]). Moreover, from the general intermediate Kaneka alcohol **8**, other statins in this family, such as pitavastatin **10** ([@bib13]) and atorvastatin **11** ([@bib32]), could be easily prepared on scales up to kilograms. Notably, asymmetric total syntheses of statins have been well documented in the literature ([@bib12], [@bib40]). However, this methodology is the first example using CO~2~ as oxygen source to construct the important chiral *syn*-1,3-diol structure. Right now, this procedure was patented and processed in a pharmaceutical company ([@bib10]).Scheme 3Pilot-Plant-Scale Synthesis of Statins

Conclusion {#sec2.2}
----------

In summary, we have developed a one-pot diastereocontrolled synthesis of chiral *syn*-1,3-diol derivatives via CO~2~ fixation/bromocyclization using *in situ*-generated ^t^BuOBr in excellent yield and with both relative and absolute stereocontrol. This transformation is tolerant of a wide range of functional groups and can easily be scaled up to the hectogram scale without racemization, providing ready access to a broad range of chiral *syn*-1,3-diol products. Further application of this method to the synthesis of statins highlighted the great synthetic capability of this methodology. Ongoing new synthetic approach toward chiral *syn*-1,3-diol-containing natural products and medicines using this method is now underway in our laboratory.

Limitations of Study {#sec2.3}
--------------------

Excess amounts of oxidant and source of bromides are generally needed. Substitutions on the alkenes also inhibited this reaction with decreased reactivity.

Methods {#sec3}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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[^1]: Lead Contact

[^2]: THF, tetrahydrofuran; EA, ethyl acetate; DCM, dichloromethane.

[^3]: General conditions: **1a** (1 mmol, 1.0 equiv), CO~2~ (x atm), ^t^BuOCl (x mmol), MBr (x mmol), solvent (6 mL).

[^4]: Isolated yields of **2a**.

[^5]: The diastereoselectivity was determined by ^1^H NMR.
